SpyBiotech Announces the Completion of Enrollment in Phase I Trial of SPYVLP01 Targeting Human Cytomegalovirus (HCMV)
2024年7月23日 - 9:00PM
ビジネスワイヤ(英語)
SpyBiotech, a biotechnology company with a novel vaccine
platform technology that can target infectious diseases, cancer,
and chronic diseases, announced today the completion of enrollment
in its Phase I trial of SPYVLP01, a vaccine candidate targeting
human cytomegalovirus (HCMV) using its Hepatitis B
virus-like-particle platform technology.
The Phase I clinical trial is assessing safety and
immunogenicity of the company’s HCMV vaccine in two different doses
in 120 healthy adults aged 18-50. The study features a six-month
dosing schedule and is being carried out in the UK. There is
currently no approved vaccine against HCMV.
“The initial results of our Phase I study are very encouraging,”
said Sumi Biswas, President, Co-founder and Chief Scientific
Officer of SpyBiotech. “This is an important step forward as we
further evaluate the safety and immunogenicity of our vaccine
targeting HCMV, a leading infectious cause of congenital
abnormalities.”
“The end of enrollment in our Phase I trial of SPYVLP01 and the
initial promising results both serve as a springboard as we move
into the next phase of company development,” said Mark
Leuchtenberger, Chief Executive Officer. “We will continue to
progress our scientific pipeline with a focus on our lead candidate
and on our EBV-focused collaboration with the University of
Oxford.”
About HCMV
Human cytomegalovirus (HCMV) is a betaherpesvirus that causes
lifelong infection in humans. HCMV has a prevalence of 55-100%
within the human population, depending on different socioeconomic
and geographical factors1. Primary HCMV infection is generally
asymptomatic in healthy hosts, but it can cause severe and
sometimes fatal disease in immunocompromised individuals and
neonates. HCMV is the leading infectious cause of congenital
abnormalities in the Western world. HCMV intrauterine infection may
cause significant morbidity, including low birth weight, hearing
loss, visual impairment and microcephaly.
About SpyBiotech
SpyBiotech is a clinical stage biotechnology company with novel
vaccine platform technologies to target infectious diseases, cancer
and chronic diseases. The company was spun out of the University of
Oxford in 2017 by Oxford Science Enterprises (OSE) and Google
Ventures (GV). The company raised $32.5 million in a Series A
equity financing in 2021. Based on science developed at the
University of Oxford, SpyBiotech’s novel vaccine platform is based
on a proprietary protein “superglue” technology which binds
antigens to vaccine delivery platforms in a way which minimizes
delivery risk and enhances immunogenicity and efficacy. This makes
it ideal for use against infectious diseases in challenging
environments, such as in the developing world, but also with
potential application in non-infectious disease settings such as
cancer. SpyBiotech has the exclusive rights from the University of
Oxford to apply, commercialize and sub-license the
SpyTag/SpyCatcher and related “superglue” technologies in vaccine
development.
Reference: 1 Gabrielle Stack, Maria Stacey, Cardiff
University, UK, British Society for Immunology
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240723460001/en/
UK Media: Elly Williamson Sodali & Co.
elly.williamson@sodali.com
US Media: Karen Sharma CG Life ksharma@cglife.com